Title: Evaluation of effects of chitosan in preventing hemorrhagic cystitis in rats induced by cyclophosphamide

Author(s): Okamura, Takehiko; Masui, Tsuneo; St.John, Margaret K.; Cohen, Samuel M.; Taylor, Rodney J.

Citation: 泌尿器科紀要 (1995), 41(4): 289-296

Issue Date: 1995-04

URL: http://hdl.handle.net/2433/115482

Type: Departmental Bulletin Paper

Publisher: Kyoto University
EVALUATION OF EFFECTS OF CHITOSAN IN PREVENTING HEMORRHAGIC CYSTITIS IN RATS INDUCED BY CYCLOPHOSPHAMIDE

From the Department of Urology, Nagoya City University Medical School
Takehiko Okamura

From the Laboratory of Pathology, Aichi Cancer Center Research Institute
Tsuneo Masui

From the Department of Pathology and Microbiology, and the Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Nebraska, USA
Margaret K. St. John and Samuel M. Cohen

From Division of Urology, in the Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
Rodney J. Taylor

Hemorrhagic cystitis is a common problem following cyclophosphamide or radiation therapy. Chitosan has been shown to be an effective hemostatic agent and promoter of wound healing in animal experiments. We evaluated the safety and efficacy of intravesical chitosan in an animal model of cyclophosphamide cystitis. Hemorrhagic cystitis was induced in female F344 rats by intraperitoneal cyclophosphamide, 100 mg/kg. Chitosan solution (0.3 ml) was instilled intravesically on day 1 (Group 1), on days 1, 3, and 5 (Group 2), or 1 hour after the administration of cyclophosphamide (Group 3). The rats in group 4 were treated with chitosan diluent on day 1 after cyclophosphamide, and the rats in group 5 received intravesical chitosan without cyclophosphamide. Sequential examination revealed decreased mortality and lower incidences of severe bladder bleeding, necrosis and inflammation in Group 3. Treatment delayed until after the appearance of the cystitis, especially repeated treatments, appeared to make the cyclophosphamide-induced changes worse. Used within 1 hour of cyclophosphamide administration, before the cystitis develops, chitosan seemed to have the possibility to inhibit the appearance of hemorrhagic cystitis. In addition to the changes in the bladder, severe changes occurred in the kidneys secondary to cyclophosphamide.

Key Words: Chitosan, cyclophosphamide, hemorrhagic cystitis, bladder instillation.

INTRODUCTION

Chitosan is a collective term applied to chitin in various stages of deacetylation and depolymerization. It is composed of poly-N-acetyl glycosamine units. This material has been shown, when mixed with whole blood, to form a tenacious coagulum. Taking note of this chemical, several investigators reported that chitosan was a good hemostatic agent in animal experiments. Hemorrhagic cystitis is a result of diffuse capillary fragility and bleeding within the damaged urothelial lining of the bladder. This clinical entity is a frequent result of cyclophosphamide therapy or radiation therapy. Current therapeutic modalities for treating this entity include withholding the causative agent, catheter drainage, bladder irrigation with normal saline, formalin or silver nitrate bladder instillations to cauterize the bladder, transurethral electrocautery, and occasionally, cystectomy and urinary diversion in order to control severe hem-
orrhage.
In this study we evaluated the safety and efficacy of intravesical chitosan in an animal model of cyclophosphamide-induced cystitis.

MATERIALS AND METHODS

Test chemicals
Chitosan was kindly supplied by Hoechst-Roussel Pharmaceuticals, Inc., (Somerville, NJ). Sterile chitosan solution contained 2 mg/ml chitosan and 2 mg/ml acetic acid. For a placebo, sterile acetic acid solution (2mg/ml) was also supplied by Hoechst-Roussel Pharmaceuticals, Inc., Cyclophosphamide was purchased from Elkins-Sinn, Inc. (Cherry Hill, NJ) and administered dissolved sterile water.

Animals
Ninety-one weanling (4 weeks old), female F344 rats were obtained from Charles River Breeding Laboratories, Inc. (Kingston, NY). Upon arrival, the rats were weighed and randomly assigned to an experimental group by a weight stratification method. They were kept in quarantine on their respective control diets for 5 days prior to study. The rats were housed 5 or 6 per cage on dry corn-cob bedding in polycarbonate cages (16 x18x20 inches) with stainless steel wire bar covers (Lab Products, Inc., Maywood, NJ). Animal rooms were maintained at a temperature of 22±3°C and 50±20% humidity on a 12-h light/12-h dark cycle. Food and water were available ad libitum. Prolab 3000 diet was purchased from Agway, Inc. (St. Mary's, OH).

Experimental procedure
A preliminary study demonstrated that a single dose of cyclophosphamide, 100 mg/kg, i.p., produced hemorrhagic cystitis in 100% of the rats.

Figure 1 shows the experimental design Group 1 consisted of 20 rats treated with a single intraperitoneal injection of cyclophosphamide at a dose of 100mg/kg body weight. After 24 hours, transurethral intravesical instillation of 0.3 ml chitosan was performed through a 23 G catheter (Argyl, Medicut “R”, Sherwood Medical Industries, St. Louis, MO) under Nembutal (Abbott Laboratories, North Chicago, IL) anesthesia. Immediately prior to and one hour after instillation, the bladder contents were emptied by light abdominal massage so that the duration of exposure to instilled compounds was consistent. Group 2 consisted of 21 rats injected with cyclophosphamide as in group 1. Intravesical instillation of 0.3ml chitosan was performed after 24 hours, and after 3 and 5 days. Group 3 contained 20 rats injected with cyclophosphamide as in group 1. Intravesical instillation of 0.3ml chitosan was performed one hour after injection of cyclophosphamide. Group 4 contained 20 rats injected with cyclophosphamide as in

<table>
<thead>
<tr>
<th>Group</th>
<th># of rats</th>
<th>0</th>
<th>1</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>9</th>
<th>21 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20</td>
<td>▼</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>▼</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>20</td>
<td>▼</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>20</td>
<td>▼</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>▼</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td>★</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

▼: cyclophosphamide 100mg/kg I.P.
★: chitosan 0.3 ml (2mg/ml) bladder instillation (nembutal anesthesia).
☆: acetic acid 0.3 ml (2mg/ml) bladder instillation (nembutal anesthesia).
●: sacrifice 5/group/time.

Fig. 1. Experimental design
group 1. After 24 hours, 0.3 ml (mg/ml) of acetic acid was instilled into the bladder instead of chitosan. A fifth group of 10 rats was used as a negative control group they were treated with intravesical instillation of 0.3 ml chitosan, but without prior cyclophosphamide injection.

The rats were sequentially killed as indicated in Fig. 1. Two to five rats each from groups 1, 3 and 4 were killed 3, 6 and 9 days post-cyclophosphamide injection. In group 2, 2 to 5 animals were killed 4, 6, and 9 days post-cyclophosphamide treatment. Five animals in group 5 were killed on day 3 post-cyclophosphamide treatment. As occasion demanded, moribund rats were killed. The last day the rats were killed was 21 days post-cyclophosphamide treatment.

At death, the liver and each kidney were observed grossly, then carefully removed and weighed. These organs were placed directly into formalin fixative. The bladders were inflated in situ with fixative, and a day later were bisected sagittally and each half cut into 3 to 4 longitudinal strips. All tissues were embedded in paraffin, sectioned, stained with hematoxylin and eosin and examined histopathologically.

Experimental data were evaluated statistically on an IBM 3090 mainframe operating system VM using the Wilcoxon rank test (for mortality), and Fisher's exact test 1 tail (for macroscopic and microscopic findings) from the Statistical Analysis System software package (SAS Institute, Inc., Cary, NC).

RESULTS

About 25% of the rats died before they were scheduled to because of cyclophosphamide toxicity excessive anesthesia. The rats were killed or found dead as shown in Table 1. The mortality in each group was (including moribund killed) 7/20 (35%) in group 1, 8/21 (38%) in group 2, 3/20 (15%) in group 3, 5/20 (25%) in group 4, 0/10 (0%) in group 5. Groups 1 and 2 were significantly different from group 5 at p<0.05 (Wilcoxon rank test). In the groups administered cyclophosphamide, the mortality was the lowest in group 3 (however, no significant difference from the other groups).

Table 2 summarizes the macroscopic findings. In groups 1, 2 and 4, white nodules, 1 mm to 5 mm in diameter, were ob-

Table 1. Numbers of rats killed or found dead at different times after cyclophosphamide injection.

<table>
<thead>
<tr>
<th>Group</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>16</th>
<th>21 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>S</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>2</td>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>S</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>S</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>S</td>
<td>5</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>S</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

S* scheduled death
M* moribund death
F* found dead
Table 2. Macroscopic findings of kidney and bladders.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th># of Rats</th>
<th>Kidney</th>
<th>Bladder</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nodule</td>
<td>Hydronephrosis</td>
</tr>
<tr>
<td>1</td>
<td>CP→Chitosan Day 1</td>
<td>20</td>
<td>6 (30%)</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>2</td>
<td>CP→Chitosan Day 1, 3, 5</td>
<td>21</td>
<td>6 (29%)</td>
<td>3 (14%)</td>
</tr>
<tr>
<td>3</td>
<td>CP→Chitosan Day 0</td>
<td>20</td>
<td>0 (0%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>4</td>
<td>CP→Acetic Acid Day 1</td>
<td>20</td>
<td>7 (35%)</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>5</td>
<td>Chitosan Day 0</td>
<td>10</td>
<td>0 (0%)</td>
<td>1 (10%)</td>
</tr>
</tbody>
</table>

* Statistical analyses were performed using Fisher’s exact test (1-tail).

b CP: cyclophosphamide.

c Significantly different from Group 1, p<0.05.

d Significantly different from Group 3, p<0.05.

e Significantly different from Group 3, p<0.005.

f Significantly different from Group 3, p<0.01.

Table 3. Histopathological findings of kidney and bladders.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th># of Rats</th>
<th>Kidney (%)</th>
<th>Bladder (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Necrotizing</td>
<td>Severe Proliferations</td>
</tr>
<tr>
<td>1</td>
<td>CP→Chitosan Day 1</td>
<td>20</td>
<td>10 (50%)</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>2</td>
<td>CP→Chitosan Day 1, 3, 5</td>
<td>21</td>
<td>11 (52%)</td>
<td>8 (38%)</td>
</tr>
<tr>
<td>3</td>
<td>CP→Chitosan Day 0</td>
<td>20</td>
<td>1 (5%)</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>4</td>
<td>CP→Acetic Acid Day 1</td>
<td>20</td>
<td>12 (60%)</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>5</td>
<td>Chitosan Day 0</td>
<td>10</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

* Statistical analyses were performed using Fisher’s exact test (1-tail).

b CP: cyclophosphamide.

c 18 rats for bladder.

d Significantly different from Group 1, p<0.05.

e Significantly different from Group 3, p<0.05.

f Significantly different from Group 3, p<0.01.

g Significantly different from Group 3, p<0.005.

h Significantly different from Group 4, p<0.05.

i Significantly different from Group 4, p<0.005.

j Significantly different from Group 4, p<0.01.

k Significantly different from Group 4, p<0.005.

l Significantly different from Group 4, p<0.001.

served in the kidneys in 29 to 35% of the rats. The nodules were homogeneous and not encapsulated. A few cases of hydronephrosis were observed in each group. Almost all of these cases involved adhesions of the bladder. Various grades of bladder hemorrhage were observed in the cyclophosphamide administered groups. The incidence was highest in group 2 (81%) (p <0.05, p<0.001, and p<0.01, compared to groups 1, 3, 4, respectively) and lowest in group 3 (20%). The incidence was similar in groups 1 and 4 (45% and 40%, respectively). Some rats had adhesions caused by severe inflammation, and this was the most common in group 2 (38%) (p<0.05, compared to the other groups). Macroscopically, no significant findings were found in the liver.

Table 3 summarizes the histopathologi-
Okamera et al.: Effects of chitosan

Fig. 2. Severe hemorrhage of bladder in rat from group 2, involving the entire thickness of the wall. Epithelial surface is at the top. H&E, ×40.

Fig. 3. Erosion and ulceration of bladder in rat from group 2, H&E, ×20.

Fig. 2. Severe hemorrhage of bladder in rat from group 2, involving the entire thickness of the wall. Epithelial surface is at the top. H&E, ×40.

Fig. 3. Erosion and ulceration of bladder in rat from group 2, H&E, ×20.

cal findings. In group 2, the incidence of severe bleeding (52%) (p<0.05, p<0.05, and p<0.001, compared to groups 1, 3, 4, respectively) (Fig. 2), erosion or ulceration (81%) (p<0.01, compared to group 3) (Fig. 3), and severe necrosis or inflammation (52%) (p<0.05, p<0.001, and p<0.005, compared to groups 1, 3, 4, respectively) of the bladder was higher than that in the other three groups injected with cyclophosphamide. None of the group 3 animals had severe necrosis or inflammation. Simple hyperplasia of the bladder epithelium was seen in all groups. Papillary or nodular hyperplasia was seen in groups 1, 2, and 5 (11%, 11%, and 10%, respectively) on day 9 or later.

Interestingly, necrotizing papillitis of the kidneys was seen in only 5% of the rats in group 3, in contrast to 50 to 60% incidences in groups 1, 2, and 4 (p<0.005, p<0.005, and p<0.001, respectively). The white nodules in the kidneys were composed of inflammatory granulation tissue by microscopic examination. Severe hyperplasia of the renal pelvis was seen in 15 to 38% of the rats in the cyclophosphamide-administered groups, and it was highest in group 2 (38%) and lowest in group 3 (15%).

Because of advanced autolytic changes, two bladders in group 1 were excluded from histopathological examination. In group 5, one rat had multiple stones composed of calcium phosphate.

DISCUSSION AND CONCLUSIONS

Chitosan is a unique hemostatic agent. Chitosan-induced coagulum does not depend on the normal clotting cascade mechanism, and the resulting "clot" does not undergo retraction like a normal clot. Furthermore, reaction does not occur with albumin, globulin, or platelets. However, the same coagulum occurs with heparinized blood, washed red cells, and defibrinated blood. Mallette et al.2) have shown in studies involving dacron grafts placed into dogs that the chitosan coagulum remains in place around the graft until replaced by ingrowth of normal smooth muscle, vaso-vasorum, and nerve fibrils. This is in direct contrast to the extensive fibrotic reaction and fibrosis that occurs around untreated dacron grafts1,2). In another study involving the effects of chitosan on capillary bleeding, Brandenberg et al.3) showed it to be an effective topical hemostatic agent when applied to surgically created central nervous system wounds in cats. In a recent study, Bartone and Adickes6) demonstrated the effect of chitosan on wounds of the genitourinary system in dogs. Wounds were made in the kidney, ureter and penile foreskin, with decreased fibrosis observed with chitosan in all tissues studied.

Hemorrhagic cystitis is a fairly common clinical problem. It is frequently caused by cyclophosphamide therapy or radiation therapy, but may be associated with vesical malignancy, bladder amyloidosis, or viral infection. Current therapeutic modalities are directed at controlling the bleeding
until healing occurs. Use of caustic agents, such as 1% formalin or silver nitrate, to control the acute bleeding often results in further damage to the urothelium. Patients in whom this entity occurs are frequently immunosuppressed, chronically ill cancer patients in whom normal healing is retarded at best and for whom the risk of infection and persistent bleeding is much greater. In addition, patients are known to be at greater risk to develop bladder cancer following successful treatment with cyclophosphamide. A further problem involved with hemorrhagic cystitis regardless of the cause is that agents currently used to treat the hemorrhagic cystitis (i.e., formalin or silver nitrate) are caustic in nature and do not infrequently result in scarring of the bladder with a significant decrease in the pliability and volume of the bladder. Such patients may develop severe urinary problems after treatment related to a poorly functioning bladder. Furthermore, the risk of repeated bleeding episodes is significant.

In this study, we evaluated whether chitosan, an agent of proven value in controlling capillary bleeding, can, when used either prophylactically or therapeutically, decrease the incidence and sequelae of hemorrhagic cystitis in an animal model. Chitosan was not therapeutic as it did not improve the hemorrhagic cystitis once it had already developed. Surprisingly, in the group treated with three instillations, the bleeding and inflammation of the bladder were increased in severity. The chitosan solution has very high viscosity, which may cause it to be adherent and irritating. Once inflammation has occurred, chitosan might have the potential to make it worse. The chitosan diluent, acetic acid, may also have irritating properties because of its acidity, which might make the inflammation worse. Furthermore, intravesical instillation itself may produce inflammation. In the group treated only with chitosan instillation without cyclophosphamide, one rat had severe inflammation with stones, providing some support for this suggestion.

By contrast, treatment with chitosan before the cystitis developed seemed to protect the bladder. The causative agent of hemorrhagic cystitis following cyclophosphamide injection has been identified as acrolein that is generated in the urine. If chitosan really protects the bladder, protection by chitosan might be caused either by adhesion to the bladder surface, preventing contact with acrolein, or by a direct interaction with acrolein, inactivating it. The incidence of severe bleeding, severe necrosis or inflammation, simple hyperplasia in the urinary bladder was significantly less than the chitosan-treated groups (Group 1 and 2) in Group 4 (acetic acid treatment after cyclophosphamide administration). No substantial difference but necrotizing papillitis was obtained in Group 4 when compared with Group 3. Acetic acid itself might have the preventing effect on cyclophosphamide-induced hemorrhagic cystitis.

In the group (Group 3) involving prophylactic intravesical administration of chitosan, necrotizing papillitis of the kidney was almost completely inhibited. The mechanism of protection is unknown but perhaps occurred by reflux of the chitosan, protecting the kidney pelvis like the bladder, or by preventing reabsorption and renal excretion of the active metabolites of cyclophosphamide and preventing bladder damage.

The finding of necrotizing papillitis was an unexpected complication of cyclophosphamide. Necrotizing papillitis is rarely a clinical problem, and it is usually observed only in patients with diabetes mellitus, pyelonephritis, or dehydration. In animal experiments, Molland showed that aspirin or phenacetin administration induced necrotizing papillitis, and ischemia and dehydration exacerbated it. Animals may have become dehydrated due to the toxicity of cyclophosphamide, resulting in ischemia of the kidney and necrotizing papillitis. More likely, cyclophosphamide in the female rat produced severe, ulcer-
Okamura et al.: Effects of chitosan

ing inflammation secondary to toxicity in
the kidney similar to that in the bladder.

In conclusion, chitosan does not have an
active therapeutic effect for hemorrhagic
Cystitis once it develops, but it may act as
a prophylactic measure against the develop-
ment of hemorrhagic cystitis and necro-
tizing papillitis secondary to cyclophospha-
amide in a rat model. Additional studies
are required to further evaluate the mecha-
nism involved and the potential usefulness,
especially for patients receiving very high
doses, such as those in bone marrow trans-
plantation protocols for the treatment of
various malignancies.

ACKNOWLEDGEMENTS

We gratefully acknowledge the advice and
technical assistance of Dr. Emily Garland and the
assistance of Deborah Coleman with the prepa-
ration of this manuscript. The studies were sup-
ported in part by a grant from Hoechst-Roussel
Pharmaceuticals, Inc., Somerville, N.J.

REFERENCES

Surg 36: 55-58, 1983
2) Malette WG, Quigley HJ and Addickes ED: Chitosan effect in vascular surgery, tissue
culture and tissue regeneration. In: Muz-
zarveli R, Jeuniaux C, Gooday C (eds) Chi-
tin in nature and technology. New York:
Plenum Publishing Corporation 435-442,
1986
3) Brandenberg G, Leibrock LG, Shuman R,
et al.: Chitosan: A new topical hemostatic
agent for diffuse capillary bleeding in brain
4) Stillwell TJ and Renson RG Jr: Cyclophos-
phamide-induced hemorrhagic cystitis. Can-
cer 61: 451-457, 1988
5) Martin RA, Daly AM, Difonzo CJ, et al.: Randomization of animals by computer pro-
gram for toxicity studies. J Am Coll Toxi-
col 3: 1-11, 1984
6) Bartone FF and Addickes ED: Chitosan: Ef-
fects on wound healing in urogenital tissue:
Preliminary report. J Urol 140: 1134-1137,
1988
7) Levine LA and Riche JP: Urological comp-
plications of Cyclophosphamide. J Urol
141: 1069-1069, 1989
8) Fairchild WV, Spence CR, Solomon HD, et
al.: The incidence of bladder cancer after
Cyclophosphamide therapy. J Urol 122: 163
-164, 1979
9) Ansell ID and Castro JE: Carcinoma of the
bladder complicating Cyclophosphamide ther-
apy. Br J Urol 47: 413-418, 1975
10) Cox PJ: Cyclophosphamide cystitis-identi-
fication of acrolein as the causative agent.
the causative factor of urotoxic side-effects
of cyclophosphamide, ifosfamide, trofosfami-
de and sufosfamide. Arzneimittelforschung
Drug Research 29: 659-661, 1979
12) Eknovan G, Qunibi WY, Grissom RT, et
al.: Renal papillary necrosis: An update.
Medicine 61: 55-73, 1982
13) Nanra RS, Chirawong P and Kincaid-Smith
P: Medullary ischemia in experimental anal-
gastic nephropathy. The pathogenesis of re-
nal papillary necrosis. Aust N Z J Med 3:
580-586, 1973
14) Molland EA: Experimental renal papillary

(Received on September 21, 1994)
(Accepted on January 2, 1995)
メスラット cyclophosphamide 誘発出血性膀胱炎に対して、chitin の一種でユニークな止血作用を有する chitosan の膀胱内注入を行い、その効果について検討を行った。F344 メスラットを用い、100 mg/kg のcyclophosphamide を腹腔内投与することにより、出血性膀胱炎を誘発し、chitosan (0.3 ml) を以下のように膀胱内注入した。第 1 日目（グループ 1）、第 1・3・5 日目（グループ 2）、cyclophosphamide 投与 1 時間後（グループ 3）。グループ 4 は第 1 日目に chitosan 溶液のみを膀胱内注入し、グループ 5 は cyclophosphamide を投与せず、chitosan のみを膀胱内注入した。趾時的に屠宰し、肉眼的、病理組織学的に検討した結果、グループ 3 において死亡率の減少と、肉眼的膀胱出血、壊死および炎症の発生率の低下が認められた。膀胱炎発症後の chitosan 膀胱内注入は、特に経口投与施行した場合、cyclophosphamide による変化を悪化させる傾向がみられた。cyclophosphamide 投与 1 時間後の投与群では、chitosan は出血性膀胱炎の発生を抑制する可能性が示唆された。さらに、これら膀胱の変化以外に、cyclophosphamide による腎の変化も認められた。

（泌尿紀要 41: 289–296. 1995）